Saba/Weinstein Sells 220,730 ECAT Shares at ~$16.44 Average
Form 4 disclosure: Saba Capital Management, L.P. and Boaz Weinstein reported sales of BlackRock ESG Capital Allocation Term Trust (ECAT) common stock on 09/02/2025 and 09/03/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Form 4 disclosure: Saba Capital Management, L.P. and Boaz Weinstein reported sales of BlackRock ESG Capital Allocation Term Trust (ECAT) common stock on 09/02/2025 and 09/03/2025. The filings show dispositions of 130,848 shares at $16.38 and 89,882 shares at $16.50, respectively. After these transactions, the reporting persons beneficially owned 28,303,266 shares (indirect).
Insights
TL;DR Insider group sold 220,730 ECAT shares across two days, reducing indirect holdings but retaining a large position.
The reported transactions are outright dispositions of common stock rather than derivative exercises or new purchases. Combined sales total 220,730 shares at average prices near $16.44, with post-transaction indirect beneficial ownership remaining in the multi‑million share range. This pattern is a liquidity event by a large shareholder rather than an ownership relinquishment.
TL;DR Director and 10% owner reported routine sales; governance disclosure is compliant and transparent.
The Form 4 lists clear dates, transaction codes (S), prices, and resulting indirect ownership levels. The filings are signed and show the reporting structure (Saba Capital Management, L.P. and Boaz Weinstein). From a governance perspective, the disclosure meets Section 16 reporting requirements and provides investors with timely information on insider dispositions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 89,882 | $16.50 | $1.48M |
| Sale | Common Stock | 130,848 | $16.38 | $2.14M |
AI-generated analysis. How Rhea-AI works. Not financial advice.